StonvexLoading…
StonvexStonvexStonvexCore line items from CRI's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-07-23 | Q2 2026 2026-04-04 | Annual 2026 2026-01-03 | Q3 2025 2025-09-27 | Q2 2025 2025-06-28 |
|---|---|---|---|---|---|
Revenue | $613.00M | $681.11M | $2.90B | $1.97B | $1.22B |
Operating Income | Not available | $28.44M | $143.93M | $59.24M | $30.15M |
Net Income | Not available | $14.34M | $91.80M | $27.58M | $15.98M |
EPS (Diluted) | $0.06 | $0.39 | $2.53 | $0.75 | $0.43 |
Total Assets | Not available | $2.48B | $2.57B | $2.47B | $2.46B |
Total Liabilities | Not available | $1.56B | $1.64B | $1.60B | $1.60B |
Cash & Equivalents | Not available | $473.44M | $487.07M | $184.19M | $338.18M |
Free Cash Flow OCF − CapEx | Not available | $-543.00K | $68.63M | $-178.97M | $-34.88M |
Shares Outstanding | Not available | 36.85M | 36.43M | 36.52M | 36.47M |